Outcome prediction in pneumonia induced ALI/ARDS by clinical features and peptide patterns of BALF determined by mass spectrometry.

BACKGROUND: Peptide patterns of bronchoalveolar lavage fluid (BALF) were assumed to reflect the complex pathology of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) better than clinical and inflammatory parameters and may be superior for outcome prediction. METHODOLOGY/PRINCIPAL F...

Full description

Bibliographic Details
Main Authors: Jochen Frenzel, Christian Gessner, Torsten Sandvoss, Stefan Hammerschmidt, Wolfgang Schellenberger, Ulrich Sack, Klaus Eschrich, Hubert Wirtz
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3184998?pdf=render
id doaj-4704e6c574e94360bc41c49b72dd94d4
record_format Article
spelling doaj-4704e6c574e94360bc41c49b72dd94d42020-11-25T00:11:43ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-01610e2554410.1371/journal.pone.0025544Outcome prediction in pneumonia induced ALI/ARDS by clinical features and peptide patterns of BALF determined by mass spectrometry.Jochen FrenzelChristian GessnerTorsten SandvossStefan HammerschmidtWolfgang SchellenbergerUlrich SackKlaus EschrichHubert WirtzBACKGROUND: Peptide patterns of bronchoalveolar lavage fluid (BALF) were assumed to reflect the complex pathology of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) better than clinical and inflammatory parameters and may be superior for outcome prediction. METHODOLOGY/PRINCIPAL FINDINGS: A training group of patients suffering from ALI/ARDS was compiled from equal numbers of survivors and nonsurvivors. Clinical history, ventilation parameters, Murray's lung injury severity score (Murray's LISS) and interleukins in BALF were gathered. In addition, samples of bronchoalveolar lavage fluid were analyzed by means of hydrophobic chromatography and MALDI-ToF mass spectrometry (MALDI-ToF MS). Receiver operating characteristic (ROC) analysis for each clinical and cytokine parameter revealed interleukin-6>interleukin-8>diabetes mellitus>Murray's LISS as the best outcome predictors. Outcome predicted on the basis of BALF levels of interleukin-6 resulted in 79.4% accuracy, 82.7% sensitivity and 76.1% specificity (area under the ROC curve, AUC, 0.853). Both clinical parameters and cytokines as well as peptide patterns determined by MALDI-ToF MS were analyzed by classification and regression tree (CART) analysis and support vector machine (SVM) algorithms. CART analysis including Murray's LISS, interleukin-6 and interleukin-8 in combination was correct in 78.0%. MALDI-ToF MS of BALF peptides did not reveal a single identifiable biomarker for ARDS. However, classification of patients was successfully achieved based on the entire peptide pattern analyzed using SVM. This method resulted in 90% accuracy, 93.3% sensitivity and 86.7% specificity following a 10-fold cross validation (AUC = 0.953). Subsequent validation of the optimized SVM algorithm with a test group of patients with unknown prognosis yielded 87.5% accuracy, 83.3% sensitivity and 90.0% specificity. CONCLUSIONS/SIGNIFICANCE: MALDI-ToF MS peptide patterns of BALF, evaluated by appropriate mathematical methods can be of value in predicting outcome in pneumonia induced ALI/ARDS.http://europepmc.org/articles/PMC3184998?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Jochen Frenzel
Christian Gessner
Torsten Sandvoss
Stefan Hammerschmidt
Wolfgang Schellenberger
Ulrich Sack
Klaus Eschrich
Hubert Wirtz
spellingShingle Jochen Frenzel
Christian Gessner
Torsten Sandvoss
Stefan Hammerschmidt
Wolfgang Schellenberger
Ulrich Sack
Klaus Eschrich
Hubert Wirtz
Outcome prediction in pneumonia induced ALI/ARDS by clinical features and peptide patterns of BALF determined by mass spectrometry.
PLoS ONE
author_facet Jochen Frenzel
Christian Gessner
Torsten Sandvoss
Stefan Hammerschmidt
Wolfgang Schellenberger
Ulrich Sack
Klaus Eschrich
Hubert Wirtz
author_sort Jochen Frenzel
title Outcome prediction in pneumonia induced ALI/ARDS by clinical features and peptide patterns of BALF determined by mass spectrometry.
title_short Outcome prediction in pneumonia induced ALI/ARDS by clinical features and peptide patterns of BALF determined by mass spectrometry.
title_full Outcome prediction in pneumonia induced ALI/ARDS by clinical features and peptide patterns of BALF determined by mass spectrometry.
title_fullStr Outcome prediction in pneumonia induced ALI/ARDS by clinical features and peptide patterns of BALF determined by mass spectrometry.
title_full_unstemmed Outcome prediction in pneumonia induced ALI/ARDS by clinical features and peptide patterns of BALF determined by mass spectrometry.
title_sort outcome prediction in pneumonia induced ali/ards by clinical features and peptide patterns of balf determined by mass spectrometry.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2011-01-01
description BACKGROUND: Peptide patterns of bronchoalveolar lavage fluid (BALF) were assumed to reflect the complex pathology of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) better than clinical and inflammatory parameters and may be superior for outcome prediction. METHODOLOGY/PRINCIPAL FINDINGS: A training group of patients suffering from ALI/ARDS was compiled from equal numbers of survivors and nonsurvivors. Clinical history, ventilation parameters, Murray's lung injury severity score (Murray's LISS) and interleukins in BALF were gathered. In addition, samples of bronchoalveolar lavage fluid were analyzed by means of hydrophobic chromatography and MALDI-ToF mass spectrometry (MALDI-ToF MS). Receiver operating characteristic (ROC) analysis for each clinical and cytokine parameter revealed interleukin-6>interleukin-8>diabetes mellitus>Murray's LISS as the best outcome predictors. Outcome predicted on the basis of BALF levels of interleukin-6 resulted in 79.4% accuracy, 82.7% sensitivity and 76.1% specificity (area under the ROC curve, AUC, 0.853). Both clinical parameters and cytokines as well as peptide patterns determined by MALDI-ToF MS were analyzed by classification and regression tree (CART) analysis and support vector machine (SVM) algorithms. CART analysis including Murray's LISS, interleukin-6 and interleukin-8 in combination was correct in 78.0%. MALDI-ToF MS of BALF peptides did not reveal a single identifiable biomarker for ARDS. However, classification of patients was successfully achieved based on the entire peptide pattern analyzed using SVM. This method resulted in 90% accuracy, 93.3% sensitivity and 86.7% specificity following a 10-fold cross validation (AUC = 0.953). Subsequent validation of the optimized SVM algorithm with a test group of patients with unknown prognosis yielded 87.5% accuracy, 83.3% sensitivity and 90.0% specificity. CONCLUSIONS/SIGNIFICANCE: MALDI-ToF MS peptide patterns of BALF, evaluated by appropriate mathematical methods can be of value in predicting outcome in pneumonia induced ALI/ARDS.
url http://europepmc.org/articles/PMC3184998?pdf=render
work_keys_str_mv AT jochenfrenzel outcomepredictioninpneumoniainducedaliardsbyclinicalfeaturesandpeptidepatternsofbalfdeterminedbymassspectrometry
AT christiangessner outcomepredictioninpneumoniainducedaliardsbyclinicalfeaturesandpeptidepatternsofbalfdeterminedbymassspectrometry
AT torstensandvoss outcomepredictioninpneumoniainducedaliardsbyclinicalfeaturesandpeptidepatternsofbalfdeterminedbymassspectrometry
AT stefanhammerschmidt outcomepredictioninpneumoniainducedaliardsbyclinicalfeaturesandpeptidepatternsofbalfdeterminedbymassspectrometry
AT wolfgangschellenberger outcomepredictioninpneumoniainducedaliardsbyclinicalfeaturesandpeptidepatternsofbalfdeterminedbymassspectrometry
AT ulrichsack outcomepredictioninpneumoniainducedaliardsbyclinicalfeaturesandpeptidepatternsofbalfdeterminedbymassspectrometry
AT klauseschrich outcomepredictioninpneumoniainducedaliardsbyclinicalfeaturesandpeptidepatternsofbalfdeterminedbymassspectrometry
AT hubertwirtz outcomepredictioninpneumoniainducedaliardsbyclinicalfeaturesandpeptidepatternsofbalfdeterminedbymassspectrometry
_version_ 1725402544678633472